West-Ward rebranded as Hikma Pharmaceuticals USA

Press enter to search
Close search
Open Menu

West-Ward rebranded as Hikma Pharmaceuticals USA

By David Salazar - 06/26/2018
West-Ward Pharmaceuticals has a new name as part of rebranding efforts by its parent company, London-based Hikma Pharmaceuticals. The company, acquired by Hikma group more than 20 years ago, will now be Hikma Pharmaceuticals USA, or simply Hikma.

“For our U.S. customers and partners the transition to Hikma will be seamless with no change to our strong portfolio of products or our ongoing commitment to deliver great customer service and our dedication to patients,” said Dan Motto, executive vice president of commercial development strategy for the U.S. injectables business said. “Beginning today, most touchpoints in the US will now bear the new Hikma logo including our building signage, our company collateral, and our website. Our updated product packaging and labeling will be rolled out over the next 12 to18 months, with our priority being to maintain consistent supply and patient safety.”

The company said that the new brand is focused on Hikma Group’s role in improving patient health worldwide through affordable and accessible medicine as it celebrates its 40th anniversary. The U.S. subsidiary’s rebrand comes at the same time as its U.K. subsidiary.

“We believe that operating all our companies as Hikma in our markets will allow us to better serve customers, be more efficient, and to build on the trusted Hikma name,” Hikma Group CEO Siggi Olafson said. We want to draw on the strengths we have around the world and unlock the power of a single, global brand.”

The company’s new coral-red logo and design system have gone live on the company’s mobile, social and web properties across Hikma Group’s market, the company said.

Related Topics